Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald L Lamm

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
The West Virginia Medical Journal|July 29, 2006
Cisplatin, gemcitabine and paclitaxel triplet chemotherapy in 50 patients with advanced or metastatic urothelial cancerThomas F Hogan, Donald L Lamm, Gisa B Schuun, et al.
Urologic Oncology|July 1, 2019
Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancerMarcus J Daniels, Emily Barry, Mark Schoenberg, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 19, 2016
Innovation in Bladder Cancer ImmunotherapyH Barton Grossman, Donald L Lamm, Ashish M Kamat, et al.
JSLS : Journal of the Society of Laparoendoscopic Surgeons|May 4, 2004
Mayo Clinic Scottsdale Experience with laparoscopic nephroureterectomyScott D Simon, Robert G Ferrigni, Donald E Novicki, et al.
The Journal of Urology|May 29, 2003
Mayo Clinic Scottsdale experience with laparoscopic nephron sparing surgery for renal tumorsScott D Simon, Robert G Ferrigni, Donald E Novicki, et al.
The Journal of Urology|March 17, 2004
Complications of laparoscopic nephrectomy: the Mayo clinic experienceScott D Simon, Erik P Castle, Robert G Ferrigni, et al.
The Journal of Urology|December 18, 2013
DNA based therapy with diphtheria toxin-A BC-819: a phase 2b marker lesion trial in patients with intermediate risk nonmuscle invasive bladder cancerOfer N Gofrit, Shalva Benjamin, Sarel Halachmi, et al.
The Journal of Urology|May 16, 2022
Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder CancerMax Kates, Ahmed M Mansour, Donald L Lamm, et al.
BJU International|January 18, 2020
Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG)Justin T Matulay, Mark Soloway, J Alfred Witjes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer GroupAshish M Kamat, Richard J Sylvester, Andreas Böhle, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
The West Virginia Medical Journal|July 29, 2006
Cisplatin, gemcitabine and paclitaxel triplet chemotherapy in 50 patients with advanced or metastatic urothelial cancerThomas F Hogan, Donald L Lamm, Gisa B Schuun, et al.
Urologic Oncology|July 1, 2019
Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancerMarcus J Daniels, Emily Barry, Mark Schoenberg, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 19, 2016
Innovation in Bladder Cancer ImmunotherapyH Barton Grossman, Donald L Lamm, Ashish M Kamat, et al.
JSLS : Journal of the Society of Laparoendoscopic Surgeons|May 4, 2004
Mayo Clinic Scottsdale Experience with laparoscopic nephroureterectomyScott D Simon, Robert G Ferrigni, Donald E Novicki, et al.
The Journal of Urology|May 29, 2003
Mayo Clinic Scottsdale experience with laparoscopic nephron sparing surgery for renal tumorsScott D Simon, Robert G Ferrigni, Donald E Novicki, et al.
The Journal of Urology|March 17, 2004
Complications of laparoscopic nephrectomy: the Mayo clinic experienceScott D Simon, Erik P Castle, Robert G Ferrigni, et al.
The Journal of Urology|December 18, 2013
DNA based therapy with diphtheria toxin-A BC-819: a phase 2b marker lesion trial in patients with intermediate risk nonmuscle invasive bladder cancerOfer N Gofrit, Shalva Benjamin, Sarel Halachmi, et al.
The Journal of Urology|May 16, 2022
Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder CancerMax Kates, Ahmed M Mansour, Donald L Lamm, et al.
BJU International|January 18, 2020
Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG)Justin T Matulay, Mark Soloway, J Alfred Witjes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer GroupAshish M Kamat, Richard J Sylvester, Andreas Böhle, et al.
Pageof 3